

# AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2009

## AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,  
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.12.2009 (Unaudited)	Quarter ended 31.12.2008 (Unaudited)	Year ended 31.12.2009 (Audited)	Year ended 31.12.2008 (Audited)
<b>1 (a) Net Sales</b>	2,371	2,699	9,744	9,833
<b>(b) Other Operating Income</b>	196	165	781	532
<b>Total</b>	2,567	2,864	10,525	10,365
<b>2 Expenditure</b>				
<b>a) Increase /decrease in stock in trade and work in progress</b>	(236)	71	(623)	104
<b>b) Consumption of raw materials</b>	762	936	3,525	3,077
<b>c) Purchase of traded goods</b>	722	331	1,918	1,583
<b>d) Employees Cost</b>	382	324	1,440	1,192
<b>e) Depreciation</b>	44	44	173	182
<b>f) Other expenditure</b>	578	571	2,006	2,022
<b>g) Total</b>	2,252	2,277	8,439	7,245

Particulars	Quarter ended 31.12.2009 (Unaudited)	Quarter ended 31.12.2008 (Unaudited)	Year ended 31.12.2009 (Audited)	Year ended 31.12.2008 (Audited)
<b>3 Profit from Operations before Other Income and Interest (1-2)</b>	315	587	2,086	2,205
<b>4 Other Income</b>	57	123	330	394
<b>5 Profit before Interest (3+4)</b>	372	710	2,416	2,599
<b>6 Interest</b>	1	2	1	3
<b>7 Profit before tax (5-6)</b>	371	708	2,415	2,596
<b>8 Tax Expense</b>	111	255	841	934
<b>9 Net Profit for the Period (7-8)</b>	260	453	1,574	1,662
<b>10 Paid-up equity share capital Face Value of Rs.10 per Share)</b>	230	230	230	230
<b>11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	8,916	7,881
<b>12 Earnings Per Share (EPS)(Rs)(Basic and diluted EPS for the period for the year to date and for the previous year</b>	11.31	19.70	68.35	72.16
<b>13 Public Shareholding</b>				
<b>- Number of Shares</b>	9,120,955	9,120,955	9,120,955	9,120 955
<b>- Percentage of Shareholding</b>	39.60	39.60	39.60	39.60

Particulars	Quarter ended 31.12.2009 (Unaudited)	Quarter ended 31.12.2008 (Unaudited)	Year ended 31.12.2009 (Audited)	Year ended 31.12.2008 (Audited)
<b>14 Promoters and Promoter group Shareholding</b>				
<b>a) Pledged/Encumbered</b>				
- Number of shares	2,365,920		2,365,920	
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	17.01%		17.01%	
- Percentage of shares (as a % of total share capital of the company)	10.27%		10.27%	
<b>b) Non-encumbered</b>				
- Number of shares	11,543,747		11,543,747	
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	82.99%		82.99%	
- Percentage of shares (as a % of total share capital of the company)	50.13%		50.13%	

## Notes:

- The above results were approved by the Board of Directors of the Company at its Meeting held on February 24, 2010.
- The Board of Directors has recommended a Final dividend of Rs. 16.50 per Equity share of Rs. 10 for the year ended December 31, 2009. An Interim dividend of Rs. 3.50 per Equity share of Rs. 10 had been paid in August 2009. The total dividend for the year ended December 31, 2009 is accordingly Rs. 20 per equity

share of Rs 10 ( Previous year: Rs.16 per Equity share). The dividend payout is 29.3% of the Net Profit for the year ended December 31, 2009.

- The Company discontinued the distribution of the anti-rabies vaccine, Rabipur from February 19, 2009, pursuant to the Award of the Arbitrator in the matter relating to the disputes between the Company, Novartis Vaccines and Diagnostics Inc. and Chiron Behring Vaccines Private Limited (CBVPL) regarding the non-renewal of the Distribution Agreement for Rabipur. The Company continues to hold 49% of the share capital of CBVPL.
- The break up of Net Sales is as follows:

### Rs Million

	Quarter ended Dec 31, 2009	Quarter ended Dec 31, 2008	Growth %	Year ended Dec 31, 2009	Year ended Dec 31, 2008	Growth %
<b>Domestic Sales-Others</b>	1,828	1,716	6.5%	7,362	6,552	12.4%
<b>Domestic Sales-Rabipur</b>	-	295	-100.0%	92	1,179	-92.2%
<b>Export Sales</b>	543	688	-21.1%	2,290	2,102	8.9%
<b>Total Sales</b>	<b>2,371</b>	<b>2,699</b>	<b>-12.2%</b>	<b>9,744</b>	<b>9,833</b>	<b>-0.9%</b>

- Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth for the year ended December 31, 2009 is 11.5%.
- The company has a single business segment namely "Pharmaceutical Business".
- Information on investor complaints is furnished below:

Pending as on Oct 1, 2009	Received during the quarter	Disposed of during the quarter	Pending as on December 31, 2009
Nil	6	6	Nil

- Date of closure of Register of Members:- April 9, 2010 to April 27, 2010 (both days inclusive)

- Date from which Dividend is payable:-On or after April 28, 2010 if declared at the Annual General Meeting to be held on April 27, 2010.
- The figures for the previous periods have been re-grouped, wherever necessary.

**AVENTIS PHARMA LIMITED**  
**DR. SHAILESH AYYANGAR**  
**MANAGING DIRECTOR**